Neurotensin receptor agonists and antagonists for schizophrenia.
Robertson
Vida B
VB
Wilson
Michael S
MS
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000453:epidemiology; D003627:Data Interpretation, Statistical; D006801:Humans; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078785:Mirtazapine; D009496:Neurotensin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D018028:Receptors, Neurotensin / Q000819:agonists* / Q000037:antagonists & inhibitors; D012107:Research Design / Q000592:standards; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010446:Peptide Fragments; D010880:Piperidines; D011720:Pyrazoles; D011804:Quinolines; D018028:Receptors, Neurotensin; C407426:neurotensin 69L; C079087:SR 48692; D008803:Mianserin; D009496:Neurotensin; D000078785:Mirtazapine; C091554:SR 142801